Novartis scores 19 points higher than Bayer on SINK's sustainability index.
Novartis is more sustainable according to SINK's open sustainability index, scoring 50/100 vs Bayer's 31/100 — a difference of 19 points.
Bayer scores 31/100 on the SINK sustainability index (Below expectations). Bayer discloses climate data comprehensively and meets SBTi targets on paper, but faces 170,000+ Roundup lawsuits, OECD complaints over deforestation, and PFAS water contamination from its agrochemical portfolio. Operational emissions fell 21.9% since 2019, yet the company relies on offsets for 2030 climate neutrality and its core business model actively drives biodiversity loss.
Novartis scores 50/100 on the SINK sustainability index (Making progress). Novartis has built credible climate infrastructure with SBTi-validated targets and absolute emission reductions across all scopes. However, it relies on carbon credits to claim 2025 neutrality, retains fossil fuel heating, and faces NGO criticism for trade association misalignment on climate policy. Nature strategy remains nascent.
Both companies are rated on the same 10-question SINK rubric: Scope 1/2/3 carbon footprint, energy source, nature and biodiversity, resource use, water, emissions trajectory, science-based targets, transparency, and controversies. Scores are 0–100, based on public data, and fully reproducible.
See the full leaderboard — 500+ companies ranked.
View full leaderboard →